On April 7, the U.S. Food and Drug Administration (FDA) approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Read more
FDA approves hepatitis C drugs for pediatric patients
Most Recent Content
For Nurse Practitioners
Quiz: Migraines and Hormones
Women are 2 to 3 times more likely than men to have migraines. Decades ago, these were attributed to women’s inability to cope with...
